Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
RNA Interference01:23

RNA Interference

26.5K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

7.7K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.7K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endocrine and cellular physiology and pathology of the insulin-like growth factor acid-labile subunit.

Nature reviews. Endocrinology·2024
Same author

Signaling Pathways of the Insulin-like Growth Factor Binding Proteins.

Endocrine reviews·2023
Same author

Fatherhood Following Treatment for Testicular Cancer: A Systematic Review and Meta-Analyses.

Journal of adolescent and young adult oncology·2020
Same author

Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).

Scientific reports·2019
Same author

IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer.

Cellular and molecular life sciences : CMLS·2019

Related Experiment Video

Updated: Sep 22, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

664

Noncoding RNA actions through IGFs and IGF binding proteins in cancer.

Aidan Kerr1, Robert C Baxter2

  • 1University of Sydney, Faculty of Medicine and Health, Kolling Institute, Royal North Shore Hospital, St Leonards, Sydney, NSW, 2065, Australia. aidan.kerr1998@gmail.com.

Oncogene
|May 21, 2022
PubMed
Summary

This review explores how noncoding RNAs (ncRNAs) interact with insulin-like growth factors (IGFs) and their binding proteins in cancer. Understanding these links may reveal new cancer prognosis and therapeutic strategies.

More Related Videos

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells
11:11

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells

Published on: April 25, 2018

8.3K
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.2K

Related Experiment Videos

Last Updated: Sep 22, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

664
Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells
11:11

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells

Published on: April 25, 2018

8.3K
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) are crucial in cancer progression, affecting cell survival, proliferation, migration, angiogenesis, and metastasis.
  • IGFBPs regulate the bioavailability of IGF-1 and IGF-2, impacting the type-1 IGF receptor (IGF1R) pathway and influencing cancer development through IGF-dependent and independent mechanisms.
  • Noncoding RNAs (ncRNAs), including microRNAs (miRNAs) and long-noncoding RNAs (lncRNAs), are involved in oncogenic pathways, but their intersections with the IGF axis in cancer are not fully understood.

Purpose of the Study:

  • To review the functional interactions between miRNAs and lncRNAs with IGFs and IGFBPs in the context of cancer.
  • To elucidate how the IGF axis mediates ncRNA actions that either promote or suppress cancer development.
  • To identify potential new avenues for cancer prognosis and therapeutic interventions by understanding the links between ncRNA and IGF pathways.

Main Methods:

  • Literature review and synthesis of existing research on ncRNAs, IGFs, and IGFBPs in cancer.
  • Analysis of functional interactions and signaling pathways involving these molecular players.
  • Exploration of intersecting pathways in non-cancer conditions to inform cancer research.

Main Results:

  • ncRNAs functionally interact with IGFs and their binding proteins, influencing cancer progression.
  • The IGF axis plays a role in mediating the pro-cancer or anti-cancer effects of ncRNAs.
  • Interactions between ncRNAs and the IGF axis are observed in various cancer types and may extend to non-cancerous conditions.

Conclusions:

  • A deeper understanding of ncRNA-IGF axis interactions is essential for developing novel cancer biomarkers and therapeutic strategies.
  • Exploring these pathways in both cancer and non-cancer conditions can uncover new opportunities for cancer control.
  • Targeting the interplay between ncRNAs and the IGF system holds promise for future cancer treatment advancements.